Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPITAL DOREMI 2
NCT05267886Phase 4Recruiting
- Sponsor
- University of Ottawa Heart Institute
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of dobutamine and milrinone in cardiogenic shock (2 arms), sponsored by University of Ottawa Heart Institute. Primary endpoint: Primary composite outcome at 12 weeks. Started Mar 2022; status: recruiting.
02
Drugs
dobutaminemilrinone
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on NCT05267886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05267886.